Prosecution Insights
Last updated: November 04, 2026

Ting Therapeutics, Inc.

Technology area: Biotechnology & Pharmaceuticals

4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days

Analysis

Ting Therapeutics, Inc. is currently managing 4 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 4 distinct examiners, indicating a diversified prosecution environment where each pending matter is reviewed by a different individual. This distribution requires a broad strategy to address the varying perspectives of multiple USPTO officials.

The portfolio spans multiple art units, matching the number of examiners and pending actions. This one-to-one ratio between actions, examiners, and art units suggests that each matter is isolated within its own administrative silo. The busiest examiner, WELLS, LAUREN QUINLAN, is responsible for 1 pending office action, reflecting a perfectly even workload distribution where no single examiner holds more than one action.

With the pending actions spread across many distinct art units, the company must navigate the specific guidelines of multiple specialized groups. The presence of many distinct examiners for the pending actions increases the variability of the prosecution process. Practitioners should prepare for unique examiner styles rather than a centralized negotiation strategy for the 4 pending matters.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

4
Total Pending OAs
3
Non-Final OAs
1
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

1
Overdue
0
Due this week
0
Due this month
0
Due in next 60 days
0
Due later

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

1
Hard (25%)
3
Medium (75%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§102 only1 (25%)
Double-patenting + other2 (50%)
Multi-statute (no §101)1 (25%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

4
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

40 h
Manual time on pending OAs
8 h
Time saved (low, 20%)
14 h
Time saved (mid, 35%)
0.3 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
WELLS, LAUREN QUINLAN 1 49.4% +60.1%
RAO, SAVITHA M 1 60.7% +29.7%
HOWELL, THEODORE R 1 66.9% +25.2%
CHONG, YONG SOO 1 43.8% +41.7%

Hard Cases (1)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18792993 Composition and Methods for the Prevention of Aminoglycoside Toxicity RAO, SAVITHA M —

Interview Candidates (4)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.

App #TitleExaminerDue in
18200148 Methods for the Prevention and Treatment of Hearing Loss CHONG, YONG SOO 80d overdue
18888396 Methods for the Prevention and Treatment of Hearing Loss using Oseltamivir WELLS, LAUREN QUINLAN —
18792993 Composition and Methods for the Prevention of Aminoglycoside Toxicity RAO, SAVITHA M —
18676439 COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF HEARING LOSS HOWELL, THEODORE R —

Top Art Units

Art UnitApps
1622 1
1691 1
1628 1
1623 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18888396 Methods for the Prevention and Treatment of Hearing Loss using Oseltamivir WELLS, LAUREN QUINLAN 1622 §102§103DP Non-Final OA — Pending Sep 18, 2024
18792993 Composition and Methods for the Prevention of Aminoglycoside Toxicity RAO, SAVITHA M 1691 §102§103 Non-Final OA — Pending Aug 02, 2024
18676439 COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF HEARING LOSS HOWELL, THEODORE R 1628 §103DP Non-Final OA — Pending May 28, 2024
18200148 Methods for the Prevention and Treatment of Hearing Loss CHONG, YONG SOO 1623 §102 Final Rejection 80d overdue Pending May 22, 2023

Managing Ting Therapeutics, Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Ting Therapeutics, Inc. have?

Ting Therapeutics, Inc. has 4 pending office actions as of November 2026, spread across 4 art units and 4 examiners.

Which USPTO examiner handles the most Ting Therapeutics, Inc. applications?

Lauren Quinlan Wells has the most, with 1 of Ting Therapeutics, Inc.'s pending office actions.

What technology area are Ting Therapeutics, Inc.'s patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month